Marloes G. M. Derks

Marloes G. M. Derks

Auto-generated profile, based on publicly available information

Marloes G. M. Derks

Department of Surgery, Leiden University Medical Center, Leiden, The Netherlands

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 June 2018 in British Journal of Cancer
Verified
Journal Article
Open access
PDF file
OGon behalf of the EURECCA Breast Cancer Group
on behalf of the EURECCA Breast Cancer Group
MDMarloes G. M. Derks
Marloes G. M. Derks
EBEsther Bastiaannet
Esther Bastiaannet
MKMandy Kiderlen
Mandy Kiderlen
DHDenise Hilling
Denise Hilling
CVCornelis J.H. van de Velde
Cornelis J.H. van de Velde
Older patients are poorly represented in breast cancer research and guidelines do not provide evidence based recommendations for this specific group. We compared treatment strategies and survival outcomes between European countries and assessed whether variance in treatment patterns may be associated with variation in survival. Population-based study including patients aged ≥ 70 with non-metastatic BC from cancer registries from the Netherlands, Belgium, Ireland, England and Greater Poland. Proportions of local and systemic treatments, five-year relative survival and relative excess risks (RER) between countries were calculated. In total, 236,015 patients were included. The proportion of stage I BC receiving endocrine therapy ranged from 19.6% (Netherlands) to 84.6% (Belgium). The proportion of stage III BC receiving no breast surgery varied between 22.0% (Belgium) and 50.8% (Ireland). For stage I BC, relative survival was lower in England compared with Belgium (RER 2.96, 95%CI 1.30–6.72, P < .001). For stage III BC, England, Ireland and Greater Poland showed significantly worse relative survival compared with Belgium. There is substantial variation in treatment strategies and survival outcomes in elderly with BC in Europe. For early-stage BC, we observed large variation in endocrine therapy but no variation in relative survival, suggesting potential overtreatment. For advanced BC, we observed higher survival in countries with lower proportions of omission of surgery, suggesting potential undertreatment.

1 November 2016 in Maturitas
Verified
Journal Article
Open access
SKSasmita Kusumastuti
Sasmita Kusumastuti
MDMarloes G.M. Derks
Marloes G.M. Derks
STSiri Tellier
Siri Tellier
ENEzio Di Nucci
Ezio Di Nucci
RLRikke Lund
Rikke Lund
RWRudi G.J. Westendorp
Rudi G.J. Westendorp
Ageing is accompanied by an increased risk of disease and a loss of functioning on several bodily and mental domains and some argue that maintaining health and functioning is essential for a successful old age. Paradoxically, studies have shown that overall wellbeing follows a curvilinear pattern with the lowest point at middle age but increases thereafter up to very old age. To shed further light on this paradox, we reviewed the existing literature on how scholars define successful ageing and how they weigh the contribution of health and functioning to define success. We performed a novel, hypothesis-free and quantitative analysis of citation networks exploring the literature on successful ageing that exists in the Web of Science Core Collection Database using the CitNetExplorer software. Outcomes were visualized using timeline-based citation patterns. The clusters and sub-clusters of citation networks identified were starting points for in-depth qualitative analysis. Within the literature from 1902 through 2015, two distinct citation networks were identified. The first cluster had 1146 publications and 3946 citation links. It focused on successful ageing from the perspective of older persons themselves. Analysis of the various sub-clusters emphasized the importance of coping strategies, psycho-social engagement, and cultural differences. The second cluster had 609 publications and 1682 citation links and viewed successful ageing based on the objective measurements as determined by researchers. Subsequent sub-clustering analysis pointed to different domains of functioning and various ways of assessment. In the current literature two mutually exclusive concepts of successful ageing are circulating that depend on whether the individual himself or an outsider judges the situation. These different points of view help to explain the disability paradox, as successful ageing lies in the eyes of the beholder.

1 September 2017 in The Lancet Oncology
Verified
Journal Article
Open access
MDMarloes G M Derks
Marloes G M Derks
EBErik J Blok
Erik J Blok
CSCaroline Seynaeve
Caroline Seynaeve
JNJohan W R Nortier
Johan W R Nortier
EKElma Meershoek-Klein Kranenbarg
Elma Meershoek-Klein Kranenbarg
CVCornelis J.H. van de Velde
Cornelis J.H. van de Velde
After 5 years of median follow-up, the Tamoxifen Exemestane Adjuvant Multinational (TEAM) trial reported no difference in disease-free survival between exemestane monotherapy and a sequential scheme of tamoxifen followed by exemestane in postmenopausal patients with early-stage, hormone receptor-positive breast cancer. As recurrence risk in hormone receptor-positive breast cancer remains linear beyond 5 years after diagnosis, we analysed long-term follow-up outcomes of this trial. The TEAM trial, a multicentre, open-label, randomised, controlled, phase 3 trial, included postmenopausal patients with early-stage hormone receptor-positive breast cancer from nine countries. Patients were randomly allocated (1:1) by a computer-generated random permuted block method (block sizes 4-8) to either 5 years of oral exemestane monotherapy (25 mg once a day) or a sequential scheme of oral tamoxifen (20 mg once a day) followed by exemestane for a total duration of 5 years. After the publication of the IES trial, the protocol was amended (Dec 13, 2004). Patients assigned to tamoxifen were switched after 2·5-3·0 years to exemestane therapy for a total duration of 5·0 years of treatment. Randomisation was done centrally in each country. Long-term follow-up data for disease recurrence and survival was collected in six participating countries and analysed by intention to treat. The primary endpoint was disease-free survival at 10 years of follow-up. The trial is registered with ClinicalTrials.gov, numbers NCT00279448 and NCT00032136; with Netherlands Trial Register, number NTR 267; and the Ethics Commission Trial, number 27/2001. 6120 patients of the original 9776 patients in the TEAM trial were included in the current intention-to-treat analysis. Median follow-up was 9·8 years (IQR 8·0-10·3). During follow-up, 921 (30%) of 3075 patients in the exemestane group and 929 (31%) of 3045 patients in the sequential group had a disease-free survival event. Disease-free survival at 10 years was 67% (95% CI 65-69) for the exemestane group and 67% (65-69) for the sequential group (hazard ratio 0·96, 0·88-1·05; p=0·39). The long-term findings of the TEAM trial confirm that both exemestane alone and sequential treatment with tamoxifen followed by exemestane are reasonable options as adjuvant endocrine therapy in postmenopausal patients with hormone receptor-positive early breast cancer. These results suggest that the opportunity to individualise adjuvant endocrine strategy accordingly, based on patient preferences, comorbidities, and tolerability might be possible. Pfizer, Dutch Cancer Foundation.

1 August 2018 in European Journal of Cancer
Verified
Journal Article
Closed access
MDM.G.M. Derks
M.G.M. Derks
EBE. Bastiaannet
E. Bastiaannet
WWW. van de Water
W. van de Water
NGN.A. de Glas
N.A. de Glas
CSC. Seynaeve
C. Seynaeve
GLG.J. Liefers
G.J. Liefers

1 July 2016 in The Oncologist
Verified
Journal Article
Open access
PDF file
MDMarloes G.M. Derks
Marloes G.M. Derks
NGNienke A. de Glas
Nienke A. de Glas
EBEsther Bastiaannet
Esther Bastiaannet
ACAnton J.M. de Craen
Anton J.M. de Craen
JPJohanna Portielje
Johanna Portielje
GLGerrit-Jan Liefers
Gerrit-Jan Liefers
Background.: Previous retrospective studies have shown that physical functioning in older cancer survivors is affected after treatment, yet prospective data are lacking. The aim of this study was to assess change in physical functioning in different age groups of patients with hormone receptor-positive breast cancer who were enrolled in the Tamoxifen Exemestane Adjuvant Multinational (TEAM) phase III trial. Methods.: Two physical parameters were assessed. Physical functioning was assessed using the European Organisation for Research and Treatment of Cancer (EORTC) QLQ-C30 questionnaire 1 year (T1) and 2 years (T2) after diagnosis. Physical activity was measured in metabolic equivalent of task (MET) hours/week at T1 and T2. Physical activity before diagnosis (T0) was assessed retrospectively at the T1 questionnaire. Patients were divided into three age groups: <60, 60–69, and ≥70 years. Decline in physical functioning was assessed using linear regression analysis. Differences in mean values of physical activity levels were calculated using repeated-measures one-way analysis of variance. Results.: A total of 431 patients were included for analysis. In all age groups, physical activity levels at T1 and T2 were significantly lower than prediagnostic physical activity levels (T0) (p < .001 for all age groups). Age ≥70 years was independently associated with decline in physical functioning between T1 and T2 (β = −4.62, 95% confidence interval −8.73 to −0.51, p = .028). Conclusion.: Patients aged 70 years or older treated with breast surgery and adjuvant hormonal therapy did not improve between years 1 and 2 after diagnosis to the same extent as did younger patients.

24 August 2015 in Annals of Clinical and Translational Neurology
Verified
Journal Article
Open access
PDF file
JTJan‐Mendelt Tillema
Jan‐Mendelt Tillema
MDMarloes G.M. Derks
Marloes G.M. Derks
PPPetra J. W. Pouwels
Petra J. W. Pouwels
PGPim de Graaf
Pim de Graaf
DRDiane F. van Rappard
Diane F. van Rappard
NWNicole Wolf
Nicole Wolf
Objective: Metachromatic leukodystrophy (MLD) is an inherited lysosomal disorder due to a deficiency in arylsulfatase A with progressive demyelination and neurological decline. This retrospective MRI study investigated the extent of cortical involvement at time of diagnosis, and clinical correlates to both conventional and regional volumetric measures of brain involvement.Methods: 3D‐T1‐weighted MRI scans were used to determine cortical thickness and surface‐based cerebral cortical gray matter (GM) and cerebral white matter (WM) volume (GMV and WMV), WM lesions, thalamus, and cerebellum. MRI‐MLD severity scores were obtained from FLAIR images. Associations between clinical and imaging data were examined using correlation coefficients.Results: Twenty patients with MLD (mean age 13.7 years, range 2–35) and 20 controls (mean age 13.9 years, range 2–40) were included. Compared with control subjects, late‐infantile, and juvenile patients (n = 14) had significantly diminished cerebral cortical GMV and thalamus volume (P < 0.05), but did not differ in WMV and cortical thickness. Adult patients (n = 6) showed significantly reduced GMV, WMV and cortical thickness (all P < 0.05). Regional analysis showed statistically significant cortical thinning in the cingulate gyrus and most pronounced thinning with age in the frontal lobe of MLD patients. Intelligence quotient (IQ) correlated with MRI‐MLD scores (r = −0.87, P < 0.001).Interpretation: Significant cerebral cortical GMV loss is already present in early stages of MLD. IQ correlates with WM severity scores and lesion volume, but not with volumetric measures. In adult presentations, there is more pronounced global atrophy with GMV and WMV loss and accelerated cortical thinning, most prominently in the cingulate gyrus and frontal lobes.